Health Care Financing Administration (HCFA) to reimburse investigational device exemption (IDE) devices:
This article was originally published in Clinica
Executive Summary
The US Department of Health & Human Services is expected to announce soon that the Health Care Financing Administration will reimburse new investigational technologies, reports Clinica's Washington correspondent, Duffy Miller. As indicated at the Utah International Medical Congress last month (see Clinica No 669/70, p 9), the FDA supports Medicare payment for "evolutionary" IDEs. HCFA is expected to be required to pay for Medicare patients enrolled in clinical trials of "advanced and promising" technology. Only products representing "refinements" of approved devices would be reimbursable - the FDA will assist HCFA in identifying these products. Medicare estimates that some $7 million will be paid next year for IDEs.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.